PrEP

Lack of information and access to health care, stigma, discrimination, criminalization, and privacy concerns are among the barriers some groups face when trying to obtain preventative HIV medications.

The burden of aging-related comorbidities was higher across every age category in women compared to men, and increased with age.

A new study revealed multiple locations across the southeast, including Georgia, Kentucky, and Florida, with areas that had high HIV risk but little-to-no preexposure prophylaxis services in the area.

Further analysis shows that 300 mg lenacapvir tablets plus an optimized background regimen can effectively reconcile a missed dose of lenacapavir injection in patients with HIV.

For adolescents and young adults affected by HIV, Google yielded higher quality information on pre-exposure prophylaxis more frequently compared to other search engines.

Investigators said pre-exposure prophylaxis rollout is efficient in settings with high HIV incidence, but not in settings with low HIV incidence.

Mobile apps can help consumers acquire medications, but few help with adherence beyond automatic refills or medication synchronization.

Optimizing efforts to treat patients using medication for opioid use disorder with cognitive dysfunction can improve PrEP treatment rates and reduce overall rates of HIV infection, a recent study indicates.

Wide-ranging options for HIV pre-exposure prophylaxis initiation in different settings and though different providers should be maintained to ensure underserved populations get adequate treatment options.

Despite an increase in HIV and poorer clinical outcomes among migrant populations, the uptake of PrEP among these individuals has been understudied.

Model produces information that can lead to individual providers identifying women who may need more targeted and more frequent HIV testing or be good candidates for preexposure prophylaxis.

Six-month preexposure prophylaxis (PrEP) dispensing supported by HIV self-testing resulted in PrEP adherence after 12 months and less visits to clinical sites.

Most tweets accurately communicated which groups of people Descovy for HIV pre-exposure prophylaxis is indicated for, although failed to mention resources about cost.

The trial will also evaluate the efficacy and safety of a new form of oral pre-exposure prophylaxis for HIV.

The primary medication therapies that can help with prophylaxis against HIV include pre-exposure prophylaxis and non-occupational post-exposure prophylaxis.

Bictegravir/emtricitabine/ tenofovir alafenamide tablets (B/F/TAF) provides long-term virologic suppression for nearly 100% of patients.

Targeted PrEP advertisements with different types of couples and sociodemographic characteristics were more eye-catching, motivating, relatable, and memorable.

Preexposure prophylaxis use for HIV continues to be lower than desired in some populations.

A new FDA policy would assess blood donor eligibility using a set of individual risk-based questions to reduce the risk of transfusion-transmitted HIV.

Evidence suggest better outcomes results when a program is responsive to the significant needs of this population.

The study will be conducted in Brazil, where PrEP use for HIV continues to be lower than desired.

Mental health interventions are a critical part of the global response to HIV, with multiple potential roles for psychiatrists and other mental health professionals.

Both barriers and facilitating factors, as well as a history of STIs, are associated with recent PrEP use among urban transgender women.

Implementing PrEP in retail community pharmacies increases patient accessibility but may be difficult to incorporate without modifying workflow.

Removing the word ‘risk’ from discussions of HIV PrEP and focusing more on environment and empowerment concerns are beneficial in this patient population.

Cabotegravir showed promising results in preventing HIV transmission in men, women, and transgender women with similar rates of adverse events to oral PrEP options.

The partnership to deliver HIV medications will reduce transportation and access barriers for patients, especially in underserved communities.

Many laws also allow physicians to decide which information they disclose to guardians or fail to address inadvertent breaches of confidentiality through insurance billing and claims.

The latest data indicate that the formulation can provide up to 6 months of full protection against multiple virus challenges.

Participants also generally prefer newer injectable pre-exposure prophylaxis compared to pills for HIV prevention.